Astha-15 is an ayurvedic polyherbal combination for the treatment of Covid-19 manufactured by Dalmia’s research arm Dalmia Centre for Research and Development (DCRD). Earlier, it had sought clinical trials to test the efficacy and safety of the drug. Now, AYUSH Ministry has approved the drug.
‘Astha’ means ‘Belief’; Astha has brought back belief in Ayurveda. Dalmia’s Astha-15 will be the first Ayurvedic drug and an indigenous formulation from India in the global market. It primarily addresses respiratory disorders in COVID infection.
“This is a proud moment for India, our own indigenous Ayurveda and Dalmia Healthcare Limited –has developed Astha-15 for the effective treatment of respiratory disorders in Covid patients,” said Sanjay Dalmia, Chairman, Dalmia Group of Companies. “We are happy to announce that the outcome of the Clinical Trial showed that Astha-15 has significantly reduced the cough and wheezing, improved the respiratory rate, and aid in the speedy recovery of Covid-19 patients with the improvement of quality of life during the treatment cycle,” he added assertively.
The drug has the following nature:
Astha has proved to treat disorders which have been found in Covid-19 patients:
After Dalmia Healthcare had sought approval for Astha-15 by conducting a clinical trial to evaluate the efficacy and safety of polyherbal combination for the treatment of Covid-19 along with standard care approved as per AYUSH/ICMR guidelines, two successful phases of trials were followed by the third one conducted on 120 patients in a government Medical Hospital in Thane. They followed the regulatory guidelines of AYUSH and the Informed Consent Declaration, Insurance Terms, and Hospital Ethics Committee approvals which are registered at DCGI to perform the clinical trial.
Astha-15 will be made available in the First Phase through prescriptions written for mild and moderate Covid patients undergoing treatment in Covid Hospitals. Further, Dalmia Healthcare will extend it to allopathic hospitals following procedures.
Dalmia Healthcare Limited (DHL), a Dalmia Group Company, has made a foray into the healthcare business in the year 2000 and offers plant-based formulations (Ayurvedic/herbal) prepared through scientific validation followed by clinical trials undertaken by its research center, Dalmia Centre for Research and Development (DCRD).